

Express Label No.: EJ000511335US
Mailing Date: November 19, 1999

DIVISIONAL-CONTINUATION APPLICATION TRANSMITTAL FORM

DOCKET NUMBER:	ANTICIPATED CLASSIFICATION OF THIS APPLICATION:	PRIOR APPLICATION SERIAL NUMBER: 09/151,821	PRIOR APPLICATION FILING DATE: September 11, 1998
22727-41	CLASS:	SUBCLASS:	ART UNIT:
		EXAMINER: Not yet Assigned	

ASSISTANT COMMISSIONER FOR PATENTS
BOX PATENT APPLICATION
WASHINGTON, DC 20231

JCS18 U.S. PTO
09/443842
11/19/99

Dear Sir:

This is a request for filing a ☒ continuation ☐ divisional application under 37 CFR 1.53(b), of pending prior Application Serial No. **09/151,821** filed on **September 11, 1998** of **Mehmet Toner, et al.** entitled **CONTROLLED REVERSIBLE PORATION FOR PRESERVATION OF BIOLOGICAL MATERIALS**

1. ☒ Enclosed is a copy of the latest inventor signed application, including the oath or declaration as originally filed.
The copy of the enclosed papers is as follows:

- | | | |
|-------------------------------------|-----------|--|
| <input checked="" type="checkbox"/> | <u>29</u> | page(s) of specification |
| <input checked="" type="checkbox"/> | <u>5</u> | page(s) of claims |
| <input checked="" type="checkbox"/> | <u>1</u> | page(s) of abstract |
| <input checked="" type="checkbox"/> | <u>5</u> | sheet(s) of drawing |
| <input checked="" type="checkbox"/> | <u>5</u> | page(s) of declaration and power of attorney (unsigned). |

I hereby verify that the attached papers are a true copy of the prior complete Application Serial No. **09/151,821** as originally filed on **September 11, 1998**.

2. ☒ 5 pages of executed declaration and power of attorney filed with Notice to File Missing parts 12/17/98.
3. ☒ (2) verified statements to establish small entity status under 37 CFR 1.9 and 1.27, copies of which are enclosed, was filed in the prior application and such status is still proper and desired (37 CFR 1.28(a)).
4. ☒ The filing fee is calculated below:

	NUMBER OF CLAIMS FILED			NUMBER EXTRA
TOTAL	36	MINUS	20	16
INDEP.	4	MINUS	4	1
<input type="checkbox"/> MULTIPLE DEPENDENT CLAIMS				

SMALL ENTITY

RATE	FEE
x 9 =	144
x 39 =	39
+130 =	
BASIC FEE	\$380.00
TOTAL	\$563.00

LARGE ENTITY

RATE	FEE
x 18 =	
x 78 =	
+ 260 =	
BASIC FEE	\$,760.00
TOTAL	

5. ☐ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Deposit Account No. **141449**. A duplicate copy of this sheet is enclosed.

6. ☒ A check in the amount of **\$ 563.00** is enclosed for payment of the filing fee.

7. ☐ A preliminary amendment is enclosed herewith.

8. ☒ Amend the specification on page 1 under "Cross-Reference to Related Applications" by inserting --This application is a continuation of Application No. 09/151,821, filed September 11, 1998.--

9. ☐ Please abandon said prior application as of the filing date accorded this application. A duplicate copy of this transmittal is enclosed for filing in the prior application file. (May be used if signed by person authorized by §1.138 and before payment of base issue fee.)

10. ☐ Priority of application U.S. Serial No. _____ filed on _____ in the U.S. is claimed under 35 U.S.C. §119.

- ☐ The certified copy has been filed in prior application serial no. _____ filed on _____.
- ☐ The certified copy will follow.

11. ☒ The prior application is assigned of record to The General Hospital d/b/a Massachusetts General Hospital and to the Massachusetts Institute of Technology.

12. ☐ A _____ month extension of time has been submitted in the parent application Serial No. _____ in order to establish copendency with the present application.

13. ☒ The power of attorney in the prior application is to Ronald E. Cahill, et al.

- a. ☒ An unsigned power appears in the original papers in the prior application.
- b. ☒ Since the signed power does not appear in the original papers, a copy of the power in the prior application is enclosed.
- c. ☐ An Associate Power of Attorney has been executed and is attached.

14. ☒ Address all future communications: (May only be completed by applicant, or attorney or agent of record)

Ronald E. Cahill, Esq.
Nutter, McClennen & Fish, LLP
One International Place
Boston, Massachusetts 02110-2699

15. ☒ Any requests for extensions of time necessary in a parent application for establishing copendency between this application and a parent application are hereby requested and the Commissioner is authorized to charge any fee associated with such an extension to Deposit Account No. 141449.

Dated: November 19, 1999



Ronald E. Cahill
Reg. No. 38,403
NUTTER, MCCLENNEN & FISH, LLP
One International Place
Boston, MA 02110-2699
(617) 439-2782

799587.1

☒ a BIBLIOGRAPHIC DATA SHEET IS ENCLOSED.

INVENTOR INFORMATION

Inventor One Given Name:: Mehmet
Family Name:: Toner
Postal Address Line One:: 100 Pilgrim Road
City:: Wellesley
State or Province:: Massachusetts
Country:: US
Postal or Zip Code:: 02481
City of Residence:: Wellesley
State or Province of Residence:: Massachusetts
Country of Residence:: US
Citizenship Country:: TURKEY
Inventor Two Given Name:: Michael
Family Name:: Russo
Postal Address Line One:: 22 Pleasant Street
City:: Wakefield
State or Province:: Massachusetts
Country:: US
Postal or Zip Code:: 01880
City of Residence:: Wakefield
State or Province of Residence:: Massachusetts
Country of Residence:: US
Citizenship Country:: US
Inventor Three Given Name:: Robert
Family Name:: Bieganski
Postal Address Line One:: P.O. Box 425845
City:: Cambridge
State or Province:: Massachusetts
Country:: US
Postal or Zip Code:: 02142-0016
Citizenship Country:: US

CORRESPONDENCE INFORMATION

Correspondence Customer Number:: 021125
Fax One:: (617)310-9782
Electronic Mail One:: rec@nutter.com
Fax Two:: (617)310-9766
Electronic Mail Two:: wcg@nutter.com

APPLICATION INFORMATION

Title Line One:: CONTROLLED REVERSIBLE PORATION FOR PRESE
Title Line Two:: RVATION OF BIOLOGICAL MATERIALS
Total Drawing Sheets:: 5
Formal Drawings?: No
Application Type:: Utility
Docket Number:: 22727-41

License US Govt. Agency:: NIH
Contract or Grant Numbers One:: DK 46270
Licensed US Govt. Agency:: NIH
Contract or Grant Number:: NS 26760
Secrecy Order in Parent Appl.?:: No

REPRESENTATIVE INFORMATION

Representative Customer Number:: 21125
Registration Number One:: 38403
Registration Number Two:: 31359
Registration Number Three:: 37596
Registration Number Four:: 32675
Registration Number Five:: 41003
Registration Number Six:: 28711
Registration Number Seven:: 30833
Registration Number Eight:: 45053
Registration Number Nine:: 40792
Registration Number Ten:: 41277

CONTINUITY INFORMATION

This application is a:: CONTINUATION OF
> Application One:: 09/151,821
Filing Date:: 09-11-1998

Source:: PrintEFS Version 1.0.1

CONTROLLED REVERSIBLE PORATION FOR PRESERVATION OF BIOLOGICAL MATERIALS

CROSS-REFERENCE TO RELATED APPLICATIONS

Not Applicable.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

This work was partially supported by NIH grants DK 46270 and NS 26760.

FIELD OF THE INVENTION

The present invention relates to the preservation of biological tissue using reversible controlled poration methods to load intracellular protective agents to preserve cells by freezing and/or drying.

BACKGROUND OF THE INVENTION

With recent advances in cell transplantation, tissue engineering and genetic technologies, the living cell is becoming an important therapeutic tool in clinical medical care. From the use of living artificial skin and bone material to treat burn and trauma victims, to bioartificial devices and direct transplantation of cellular material to treat the increasingly long list of genetically-based diseases, living cells are increasingly incorporated into comprehensive treatment. In such a construct, the exogenous cells perform the multitude of complex tasks which the diseased tissue cannot. Successful long-term preservation and storage of mammalian cells is critical to the success of this type of medical care. Current preservation technology, including cryobiological technology, often requires rather complicated freezing and thawing protocols which may be specific for cell type, each requiring

some variation of a cryopreservation agent (CPA) cocktail to help the cell overcome freezing stresses.

5 Most traditional cryopreservation protocols include the addition of 1.0-2.0 M of penetrating CPAs such as DMSO, glycerol, and ethylene glycol. Small carbohydrate sugars, such as trehalose, sucrose, and maltose have physicochemical properties (e.g., glass formation) for use as CPAs which are superior to traditional CPAs, however, mammalian cell membranes are not practically permeable to these materials.

10 In order to provide the preservation of mammalian cells necessary for application of living cells as a therapeutic tool in clinical medical care, new protocols for preserving living nucleated cells using low levels of non-toxic preservation agents and having simple procedures applicable to a variety of cells must be developed.

SUMMARY OF THE INVENTION

25 The present invention provides a method for preserving living cells that begins with the reversible poration of the cell membranes. In one preferred embodiment, this reversible poration is accomplished using H5 α -toxin, a genetically engineered mutant of *Staphylococcus aureus* α -toxin having five of its native residues replaced with histidines. Once porated, the biological material is loaded to a predetermined intracellular concentration with a bio-preservation agent such as a sugar having bio-preservation properties. The method of the invention may advantageously use low levels, less than or equal to about 1.0 M, of intracellular sugar and may use intracellular sugar alone as the protective agent, in combination with other intracellular sugars, or in combination with traditional penetrating CPAs.

5 The biological material is then prepared for storage. In general, the material may be prepared for storage by freezing and/or drying. In an exemplary embodiment, a simple plunge freezing technique is shown to have very high yield in the method of the invention. A vacuum drying protocol is also shown to result in post storage viability. In addition, air drying as well as freeze drying techniques may be employed.

10 Once the biological material is prepared for storage, it is stored in a manner appropriate to its preparation. Frozen material can be stored at cryogenic temperatures and dried material can dry stored at ambient or other temperatures as appropriate. Recovery of stored material is also appropriate to the method of its preparation for storage. Dried material can be rehydrated and frozen materials can be thawed. Cell membrane poration reversal may also be accomplished during the recovery step. When using H5 α -toxin, poration reversal may be accomplished by addition of μ M concentrations of Zn^{2+} ions. This may be accomplished by placing the cells into a culture medium having a sufficient concentration of such ions.

BRIEF DESCRIPTION OF THE DRAWINGS

1 The invention will be more fully understood by reference to the following detailed description when considered in conjunction with the accompanying drawings, in which:

FIG.1 is flow chart showing steps in the method of the invention;

25 FIGS. 2A-G illustrate functional testing of cells loaded with 0.4M intracellular trehalose, plunge frozen in liquid nitrogen, and thawed at 37°C; FIGS. 2A, C, E and G illustrate plating efficiency at 3 hours; FIGS. 2B, D, F and G illustrate population survival and growth at 18 hours;

FIG. 3 illustrates the effects of trehalose in the method of the invention as an intracellular protective agent for 3T3 fibroblasts plunge-frozen in liquid nitrogen and thawed at 37°C;

5 FIG. 4 shows the effects of trehalose concentration in the method of the invention on the survival rate for 3T3 fibroblasts plunge-frozen in liquid nitrogen and thawed at 37°C; and

10 FIG. 5 illustrates fibroblast viability after vacuum drying according to the method of the invention estimated by counting attached cells with characteristic spread morphology and the ability to grow and divide.

DETAILED DESCRIPTION OF THE INVENTION

A method for preserving biological tissue of the invention, illustrated in FIG. 1, starts with the selection or isolation of the cells or tissue to be preserved 10. While the method of the invention may be used for the preservation of any biological material having lipid membranes, it is most useful for the preservation of living nucleated cells and, in particular, mammalian cells such as fibroblasts, hepatocytes, chondrocytes, keratinocytes, islets of Langerhans, granulocytes, and hematopoietic cells including bone marrow cells, platelets, red blood cells and others.

25 The target cells are then porated or permeabilized 20 to facilitate the loading of a bio-preservation solution. Preferably, the target cells are reversibly porated, that is, pores are opened in the cell membranes of the target cells, but the poration process is controllably reversible as described herein. In one embodiment of the invention, the cell membranes are permeabilized by a genetically engineered mutant of *Staphylococcus aureus* α -toxin known as H5 (due to the replacement of five of its native residues with

histidines). The structure of H5 is described in Song et al., "Structure of Staphylococcal α -hemolysin, a heptameric transmembrane pore," *Science*, **274**, 1859-1866 (1996). H5, a 293 amino acid, 34 kDa protein forms uniform 2-nm homoheptameric transmembrane pores upon introduction into lipid bilayers. The amount of poration in the cell membranes is dose-dependent and the uptake of sugars through these pores is rapid. [Russo et al., "Reversible permeabilization of plasma membranes with an engineered switchable pore," *Nature Biotech.* **15**, 278-282 (1997).]

Due to a targeted mutation, H5 pores are uniquely capable of being toggled between an open and closed state by the removal or addition of μM concentrations of Zn^{2+} ions, respectively. [Walker et al., "A pore-forming protein with a metal-actuated switch," *Protein Eng.* **7**, 655-662 (1994); Bayley, H., "Building doors into cells," *Sci. Am.* **277**, 62-67 (1997).] The activity of the switch allows permeabilized cells to regain their original permeability and, as a result, maintain the viability and ultra-structural integrity.

Other poration agents may also be used with the method of the invention to reversibly porate target cells. Other variants of the *Staphylococcus aureus* α -toxin are available having different poration characteristics. In addition, under certain conditions it is possible to create reversible pores in cell membranes using wild type *Staphylococcus aureus* α -toxin (WT). WT may not be stable in all membranes when the cells are metabolically active (e.g., in a culture medium). As a result, for cells that can remain metabolically active for a longer period of time than the WT pores remain stable, the cells can shed even WT pores to reverse the poration effect. While some cells are too sensitive to survive for the required amount of time,

other cells, such as 3T3 fibroblasts, may remain active in a porated state for up to 30 minutes and could be reversibly porated using WT.

5 Typically an H5 pore is about 2 nm in diameter. This size allows molecules having a molecular weight of up to about 1000 to enter the target cells through the H5 pores and permits many otherwise non-permeating bio-preservation agents to be used intracellularly. Other self-assembling membrane toxins capable of opening larger pores can be used or modified for use with the invention. While the application of larger pores may permit the use of larger molecules as intracellular bio-preservation agents, larger pores can have damaging effects on the target cell as well. For example, if the pores are large enough to admit the porating agent itself into the target cell, the porating agent may excessively permeabilize internal membranes and potentially cause irreparable damage to the target cell.

10 The target cells may be prepared for poration by trypsinizing, washing and suspending in a HEPES (N-[2-Hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid]) Buffered Saline (HBS) solution. Preferably, all cell preparation should occur in HBS so that no antibodies against the porating agents or proteolytic enzymes compromise the porating process. In order to porate the target cells, the HBS suspending solution should also contain a porating agent such as H5. As in the examples described below, the ratio of porating agent to target cell in the solution may be 2×10^6 cells/ml of the target cells to 25 $\mu\text{g/ml}$ of porating agent. The cells should be incubated in the porating agent containing solution for 10 minutes to allow for proper pore formation. [Walker et al., "An intermediate in the assembly of a pore-forming protein trapped with a genetically engineered switch," *Chem. Biol.* 2, 99-105 (1995).] Of course, the precise amounts and times recited herein may be varied by a person of ordinary skill in the art in keeping with the invention

where necessary to account for varying circumstances and desired effects. For example, some target cells may have receptors for H5 and may exhibit increased poration.

5 Following the permeabilization or poration step 20, a bio-preservation agent is loaded into the porated cell 30. The poration step of the invention allows otherwise non-permeating bio-preservation agents to be used intracellularly. As used herein, the term "non-permeating" refers to a compound that does not permeate the cell membrane of a mammalian cell under normal conditions in the necessary amounts in a reasonable amount of time (minutes to hours). These bio-preservation agents can include sugars as well as other non-permeating compounds either alone, mixed together, or in solution with other traditional bio-preservation agents. It is also possible that new bio-preservation agents will be synthesized specifically for intracellular application through pores of the type described herein.

10
25 Sugars having a stabilizing or preserving effect on biological material are especially useful in the present method. Exemplary sugars include trehalose, glucose, sucrose and maltose. Trehalose, a non-reducing disaccharide of glucose that is normally impermeant to mammalian cell membranes, is the most preferred sugar for use with the present method. It has an exceptional ability to stabilize and preserve proteins, viruses, and bacteria as well as an unusual ability to form stable glasses at high temperatures. Trehalose has physicochemical properties for use as a mammalian cell cryoprotective agent (CPA) that are far superior to traditional agents. Further, trehalose, contained in many food products, is relatively non-toxic and may allow for cryopreservation protocols which do not required CPA removal, resulting in an infusible end product. Sucrose, which has

properties similar to those of trehalose and which is widely available and relatively inexpensive, may also be preferred for certain applications.

5 Sugar may be added to the cell suspension in an HBS solution to the final desired concentration. Porated cells may be incubated in the sugar containing solution for 45 minutes. A 45 minute interval has been demonstrated to be sufficient for the uptake of sucrose and trehalose for 3T3 fibroblast cells porated with 25 $\mu\text{g/ml}$ H5. Of course the length of time required for sugar uptake may vary with the type of cell and the level of cell poration. Sugar uptake may be measured by both the uptake of radiolabeled sugar into porated cells as well as by the volumetric response of porated cells placed in a hypertonic sugar solution, yielding statistically correlative results.

10 Most traditional cryopreservation protocols include the addition of 1.0-2.0 M of penetrating cryoprotectants (CPAs) such as DMSO, glycerol, and ethylene glycol. However, using the method of the invention, small carbohydrate sugars such as trehalose, sucrose and maltose, to which mammalian cell membranes are not practically permeable, may be loaded to concentrations less than or equal to about 1.0 M, preferably less than or equal to about 0.4 M, and most preferably, the suspended, porated cells are loaded with about 0.2 M sugar.

25 In addition, reversible poration can improve the loading of conventional, permeating CPAs. Conventional CPAs used in conventional preservation procedures require tedious loading and removal steps. Typically, when a cell is exposed to a penetrating CPA such as DMSO, the cell initially shrinks because the permeability of the plasma membrane to water is significantly greater than its permeability to DMSO. Next, as the DMSO slowly penetrates the membrane, the cell swells until equilibrium is achieved

and loading of the CPA is complete. If the CPA is fully loaded in one step (e.g., 1-2 M DMSO), the initial cell shrinkage is fast and excessive, resulting in "osmotic" damage and cell death.

5 To prevent cell death, conventional CPAs are added in multiple steps. Typically, each step (depending, of course, on cell type) takes 15 to 45 minutes to load approximately 0.5 M CPA. The overall load process can thus take from 30 minutes to 2 hours or more. Similar circumstances occur during removal of the CPA from the cells. This long exposure to CPAs such as DMSO is "toxic" and can cause cell lysis. Applying conventional CPAs in the method of the invention using a reversible poration step increases the permeability to penetrating CPAs and accordingly lessens cell shrinkage and CPA loading times. As a result, the method of the invention can decrease both "osmotic" and "toxic" injuries, even using conventional CPAs.

10 It may also be beneficial to add certain high molecular weight bio-preservation agents that do not permeate through the pores. One such agent is raffinose. Raffinose attracts water that may diffuse into the biological material by forming a pentohydrate and stabilizes the glassy state against increases in moisture content (e.g. though cracked vials, etc.). Dextran of various molecular weights, having good glass formation properties, may be used extracellularly to allow increases in the storage temperature of a frozen stored sample. Other large molecules which do not permeate through H5 or similar pores may also be used extracellularly with the method of the invention to enhance the outcome of a particular preservation protocol.

25 Following the bio-preservation agent loading step 30, the biological material is prepared for storage 40. A variety of methods for freezing and/or drying may be employed to prepare the material for storage. In particular,

three approaches are described herein: vacuum or air drying 50, freeze drying 60, and freeze-thaw 70 protocols. Drying processes have the advantage that the stabilized biological material may be transported and stored at ambient temperatures.

5

In contrast to current cryobiological technology which often requires complicated freezing and thawing protocols which may need to be specific to each type of cell being preserved, the method of the invention allows for a simple freeze-thaw protocol having a high survival rate, making cold storage a good choice as well. In the simple freezing step 80 of the invention, approximately 1 ml of cell suspension (10^6 cells/ml) may be placed into a cryovial, clipped into a cryovial holder, and plunged into liquid nitrogen (LN_2) for a sufficient time to bring the suspension to a cryopreservation temperature.

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202

Freezing and Drying: Impact on Product Quality," *Cryobiol.* 33, 14-26 (1996).] and such protocols may be used to prepare cell suspensions for storage with the method of the invention.

5 An evaporative vacuum drying protocol 130 useful with the method of the invention for preserving 3T3 murine fibroblasts may include placing 20 μ l each into wells on 12 well plates and vacuum drying for 2 hours at ambient temperature. Of course, other drying methods could be used, including drying the biological material in vials.

10 Biological material prepared in this manner may be stored dry 140, and rehydrated by diluting in DMEM which contains serum (and sufficient Zn^{2+} to seal the H5 pores) to reverse the cell poration 170 and promote cell recovery.

 A method of the invention using freeze drying 60 to prepare the biological material for storage 40 begins with freezing 80 the cell suspension. While prior art freezing methods may be employed, the simple plunge freezing method described herein for the freeze-thaw method may also be used for the freezing step 80 in the freeze drying protocol.

 After freezing, a two stage drying process 150 is typically employed. In the first stage, energy of sublimation is added to vaporize frozen water. When freeze drying biomaterials, the primary criterion for selecting the temperature of the primary drying phase is that it must be below the glass phase transition temperature of the freeze concentrated solution to avoid collapse and undesirable chemical reactions. In general, the highest possible temperature that will not damage the sample should be used so that
25 sublimation will occur quickly. Typically, the primary drying occurs at a

constant temperature maintained below the glass transition temperature for the freeze concentrated solution.

5 Secondary drying is performed after the pure crystalline ice in the sample has been sublimated. Secondary drying cannot take place unless the temperature is raised above the glass phase transition temperature of the freeze concentrated solute, however, it is crucial that sample temperature not rise above the collapse temperature above which the specimen is believed to mechanically collapse due to viscous flow.

10 Freeze dried materials can be stored 140, hydrated 160 and the cell poration reversed 170 in the same manner as described above for vacuum drying. Viable cells may then be recovered 180.

EXAMPLE 1 — FREEZE-THAW PROCEDURE

CELL CULTURE

25 Examples were performed using NIH/3T3 murine fibroblasts (American type Culture Collection, Rockville, MD) cultured in Dulbecco's Modified Eagle Medium (DMEM; Life Technologies, Inc., Gaithersburg, MD) supplemented with 10% bovine calf serum (BCS, JRH Biosciences, Lenexa, KS) and incubated at 37°C with 10% CO₂ in air. At confluence, approximately every three days, cells were trypsinized in 0.1% trypsin solution (Life Technologies) and replated at a 40 fold reduction in cell number.

CELL PORATION

Fibroblasts in the log-phase of growth were trypsinized in 0.1% trypsin solution, washed twice in DMEM with BCS, and suspended (2×10^6 cells/ml) in HEPES Buffered Saline (HBS: dH₂O 130 mM NaCl, 7.2 mM KCl, 20 mM HEPES (N-[2-Hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid])); all Sigma, St. Louis, MO) at a pH of 7.4. As indicated in Table 1 and FIG. 3, HBS suspending solution also contained either (i) 25 μ g/ml of H5, the site-directed zinc-switchable mutant of *Staphylococcus aureus* (*S. aureus*) α -toxin (produced and purified as in Walker et al., "A pore-forming protein with a metal-actuated switch," *Protein Eng.* 7, 655-662 (1994)), (ii) 25 μ g/ml of wild type *S. aureus* α -toxin (Sigma; WT), or (iii) no addition. Because of the variability among protein preparations, the hemolytic activities of the two porating proteins (H5 and WT) were equalized by measuring the release of hemoglobin from rat erythrocytes at OD 405 as adapted from Hildebrand et al., "*Staphylococcus aureus* α -toxin: Dual mechanism of binding to target cells," *J. Biol. Chem.* 266, 17195-17200 (1991). Though there was little difference in their activity (50% release of hemoglobin at 0.1 μ g/ml after 3 hours of poration), the concentration of WT protein solution was slightly reduced so that its activity matched the activity of the 25 μ g/ml of H5. Cells were incubated in the toxin containing solutions for 10 min to allow for proper pore formation.

SUGAR LOADING

Following poration, 0-1.0 M trehalose (final concentration) in HBS solution (Sigma) was added to the cell suspension, as indicated in FIG. 4. To allow for trehalose uptake, porated cells were incubated in the solution for 45 min. A 45 min interval has been demonstrated to be sufficient for the uptake of sucrose, a disaccharide similar to trehalose. [Russo et al., "Reversible permeabilization of plasma membranes with an engineered switchable pore,"

Nature Biotech. **15**, 278-282 (1997).] This uptake was measured by both the uptake of radiolabeled sugar into porated cells as well as by the volumetric response of porated cells placed in a hypertonic sugar solution, yielding statistically correlative results. By repeating the volumetric experiments using hypertonic trehalose solutions and 25 $\mu\text{g/ml}$ of porating agent, volumetric equilibration over 90% over a 45 min interval was achieved, indicating the equilibration of intracellular trehalose concentration with that of the suspending solution.

PRE-FREEZE EXPERIMENTS

As specified in Table 1 and FIG. 3, fibroblasts were treated with varying poration and trehalose schemes by the methods described above. To determine the effects of these pre-freeze treatments on cell viability and function, cells were then assayed by flow cytometric analysis and by measuring cellular plating efficiency, clone forming ability, and population growth as described below.

CRYOPRESERVATION PROTOCOL

Following a variety of poration and trehalose treatments as indicated in FIGS. 3 and 4, 0.9 ml of the cell suspension (10^6 cells/ml) was placed into a 1.9 ml cryovial (Nalgene, Rochester, NY), clipped into a cryovial holder (TS Scientific, Perkaise, PA), and plunged into liquid nitrogen (LN_2) and stored there for 60 minutes. Individual vials were then thawed in a 37°C water bath with continuous, mild agitation for 5 min. For later analysis by the methods described below, thawed cells were diluted in serum containing DMEM which contained sufficient Zn^{2+} to seal the H5 pores and promote cell recovery.

FLOW CYTOMETRY

At 15 minutes, 1 hour, and 2 hours following either the pre-freeze cell preparation (poration and trehalose loading) or after the freeze-thaw protocol, two fluorescent dyes, calcein (5 μ M; Molecular Probes; Dugene OR) and ethidium homodimer (EH; 10 μ M; Molecular Probes) were added to HBS cell suspensions to assess viability of the cells. Calcein fluoresces green (510 nm) when retained intracellularly and indicates a live cell with an intact cell membrane, while EH fluoresces red (617 nm) when bound to DNA and thus stains the nucleus of a dead cell. Following calibration, cells were run at low flow rates through the Beckton Dickinson FACSCalibur flow cytometer (San Jose, CA) to measure forward and side scatter as well as take emission readings at 530 ± 30 nm and 63 ± 022 nm of 10,000 particles. Cells, as indicated by size and ganularity, were evaluated for their emissions at the two wavelengths indicated above. High green and low red fluorescence was scored as live, while low green and high red were scored as dead; those displaying low or high values for both were scored as dead. Since the live/dead data is delivered as a percentage, total cell yield was determined by counting on a hemocytometer (Baxter, McGaw Park, IL). Those which do not appear in the total yield, presumably cells which have lysed and dispersed, less those lost by cell handling and transfer as determined by control experiments, were likewise scored as dead.

PLATING EFFICIENCY

Following either the pre-freeze cell preparation or after the freeze-thaw protocol, each cell suspension was diluted in 12 ml DMEM with BCS and plated in a P75 tissue culture flask (Falcon, Franlin Lakes, NJ). After three hours, flasks were washed twice with HBS and those cells remaining in the flask were trypsinized and counted using a hemocytometer. For pre-freeze experiments, reported values are the number of cells which were successfully

plated normalized to the total number of cells input to the system following preliminary cell handling. For freeze-thaw conditions, reported values are the number of cells which successfully plated normalized to the total number of cells input to the system following preliminary cell handling and any toxin treatment. Micrograph images were obtained on a Nikon Diaphot microscope (Nikon Ph2, NA-.4; Tokyo, Japan) at 120x magnification and captured with Metamorph imaging software and are shown in FIGS. 2A-G.

CLONOGENIC ASSAY

For each condition, approximately 200 of the cells that had plated in 3 hours were replated in a P75 for one week. To obtain 200 fibroblasts, cells were diluted to 2×10^5 cells/ml, and $1 \mu\text{l}$ of cell solution was introduced into a P60 petri dish (Falcon) containing 12 ml of DMEM with BCS. After one week, cells were fixed by a 0.5% glutaraldehyde wash and stained by Rhodamine B (Sigma) to enhance colony visibility. The number of colonies formed was determined by visual inspection.

SURVIVAL AND GROWTH

Following either the pre-freeze cell preparation or after the freeze-thaw protocol, the cell suspensions for each condition were diluted in 12 ml of DMEM with BCS and plated in P75 flasks. After 18 hours, approximately two population doubling cycles, flasks were washed twice with HBS. Fibroblast populations were then trypsinized and counted on a hemocytometer. For pre-freeze measurements, data was normalized to the unporated control case with no trehalose addition. For post-thaw experiments, reported values are the total number of cells in each flask normalized to an unfrozen control population otherwise treated identically to the experimental condition.

STATISTICAL ANALYSIS

5 Data were analyzed by ANOVA factorial and evaluated with Fisher's Post-Hoc Test for at least 97% confidence ($p \leq 0.03$). Pre-freeze flow cytometry, plating efficiency, and clonogenic experiments were repeated at least twice, and 18 hours growth experiments were repeated at least three times. For all experiments, at least two independent measurements were performed. Data reported are normalized averages of total viable and functional cell populations at indicated time points \pm the standard error of the mean (SEM).

EXAMPLE 2 — VACUUM OR AIR DRYING PROCEDURE

10 The efficacy of intracellular trehalose for vacuum dried fibroblasts was also tested. NIH/3T3 murine fibroblasts, prepared as in Example 1, were resuspended in phosphate buffered saline (PBS) solution and the cell density was counted. Cell density was then adjusted to 100,000 cells/ml by diluting with PBS and the sample was divided into three equal aliquots of 4.0 ml each. To each aliquot, 1.0 ml of 25 μ g/ml H5 was added, reducing cell density to 8×10^4 . The aliquots were incubated at room temperature for 15 minutes with occasional mixing.

In the first two aliquots, enough 1.0M stock solution of either trehalose or sucrose in PBS was added to obtain a final sugar concentration of 0.3M. In the third aliquot, an equivalent amount of PBS, without sugar, was added.

25 The three aliquots were dispersed in triplicate wells at 20 μ l/well into four duplicate 12-well plates. Two of the twelve well plates were incubated at 37°C and 10% CO₂ as controls. The remaining two plates were vacuum dried for 2 hours at ambient temperature. After drying, the dried samples were rehydrated and the poration reversed with serum containing DMEM.

5
10
Viability assays were performed by counting attached cells at 3 hours, and cells that remained attached and divided during the next 24 hours. The experiments were repeated three times. As shown in FIG. 5, an average of 48 ± 3 cells that successfully attached at three hours for the trehalose sample, and 36 ± 3 for the sucrose sample. Adjusting for cell loss due to handling, poration, etc. using the control samples, survival rates of 4% for the cells dried in trehalose and 3% for the cells dried in sucrose were obtained. Periodic microscopic examination of the attached cells over the next 24 hours indicated that the attached cells were able to maintain the characteristic spread morphology and undergo proliferation.

RESULTS

The examples demonstrate that 0.2 M of intracellular trehalose alone is sufficient to provide protection for over 80% of the 3T3 fibroblasts cryopreserved in a simple liquid nitrogen plunge protocol. This concentration is five-fold to an order of magnitude lower than the functional concentrations of traditional CPAs such as Me_2SO and ethylene glycol. Further, this protocol allowed for the preservation of 1 ml samples, and did not have a CPA removal requirement. Based on these results, the method of the invention allows a simple cryopreservation protocol for mammalian cells.

25
To illustrate this point, a variety of assays were implemented to evaluate the condition of the cells at various time points following the uptake of trehalose as well as after the freeze-thaw cycle. At early time points, 15 and 60 min after treatment, cell viability was evaluated by assaying the integrity of the cell membrane with a double-label fluorescent stain. Next, after three hours in culture, we tested the normal ability of these cells to attach to the polystyrene substrate and spread, taking on an elongated spindle-like shape. Finally, cells which attach should then secrete extracellular matrix

and undertake the complex task of cell division. Because it involves a complex series of steps involving DNA replication, spindle formation, and protein synthesis, mitosis is an ideal marker for the functional integrity of fibroblasts. Thus, incorporating both the death of cells as well as the ability of surviving cells to divide, the population's growth over 18 hours is indicative of the overall freezing damage suffered by the cells.

As a baseline for the freezing results, the condition of cells following poration and exposure to trehalose was evaluated. Overall, these data for 18 hours growth indicate that over 95% of fibroblasts can withstand the osmotic shock of being placed into 0-0.4 M trehalose, with porated cells suffering only an additional 10% loss. Since fibroblasts reach their minimum volume when exposed to about 0.4 M trehalose (data not shown), the excessive dehydration and osmotic forces caused by concentrations higher than this threshold are most likely responsible for their loss of viability. Porated cells do not shrink to the same degree as non-permeabilized cells due to the altered water and solute transport properties of permeabilized cell membranes. They, therefore, seem to withstand the osmotic insult more readily. Moreover, the engineered H5 switch, in combination with this osmotic advantage, causes the H5 treated cells to outperform both other conditions by 20-50% for much of the upper range of trehalose concentrations. Based on these and previous data, trehalose loading was targeted at 0-0.4 M for the design of freezing protocols. This range is comparable to the trehalose concentrations used for protein and virus preservation. Since trehalose is non-toxic at these concentrations, freezing protocols were designed without a CPA removal step.

EFFECT OF PORATION AND TREHALOSE CONCENTRATION ON NON-FROZEN SAMPLES

To maximize the final post-thaw survival of the samples, the pre-freeze treatment steps were optimized, finding conditions for permeabilization and trehalose loading which were minimally damaging to cells. Pre-freeze control experiments were performed under a variety of permeabilization and trehalose conditions to measure the amount of cell loss attributable to each stage of treatment. Overall, large numbers of fibroblasts, over 85%, maintained viability and function following permeabilization by either WT or H5 either with or without trehalose addition. The complete set of pre-freeze control data is reported in Table 1. These data were normalized to cell populations following a 4% loss resulting from cell handling (pipetting, centrifugation, etc.) as measured by hemocytometer.

TABLE 1

Evaluation of Pre-freeze and Post Thaw Cells Porated and Loaded with
Trehalose

Pre-Freeze Conditions

H5/WT	0.4M Trehalose	Flow Cytometry (1h)	Plating Efficiency (3h)	Survival and Growth (18h)
-	-	94.5±3.3	91.5±1.5	100
-	+			98.4±2.6
WT	-	95.0±1.0	92.2±1.8	90.0±3.6
WT	+	78.0±3.0	80.0±3.0	87.4±0.9
H5	-	91.9±4.6	87.5±5.6	91.5±3.9
H5	+	85.1±3.1		84.2±5.8

Post-Thaw Conditions

H5/WT	0.4M Trehalose	Flow Cytometry (1h)	Plating Efficiency (3h)	Survival and Growth (18h)
-	-	4.5±3.5	0.0±0.0	0.0±0.0
-	+	45.0±8.8	11.2±2.1	14.2±8.9
WT	-	12.1±4.9	0.0±0.0	0.0±0.0
WT	+	81.3±1.2	19.3±7.3	16.9±3.6
H5	-	13.2±4.9	0.8±0.8	0.0±0.0
H5	+	79.0±6.4	66.1±6.3	70.8±2.1

Specific experiments were performed to evaluate the effect of simply suspending cells in HBS as would occur during the loading of trehalose. Flow cytometric analysis with live/dead stain indicated that $3.0 \pm 0.4\%$ of the cell population was not viable following a two hour of exposure to HBS. At three hours, cells suspended in DMEM with serum plated and spread effectively with no additional losses. Finally, by 18 hours, the cell populations increased by a factor of 2.25, indicating a baseline for normal cell growth and population doubling dynamics. Similarly, the survival and growth of non-porated cells suspended in 0.4M trehalose in HBS (98.4 ± 2.6) was not statistically different from that of the population suspended in HBS alone ($p=0.777$).

To better understand the consequences of the trehalose loading protocol, the effect of poration and trehalose treatment on the viability and function of unfrozen fibroblasts was quantified by evaluating the condition of cells porated with 25 $\mu\text{g/ml}$ of a porating agent, either alone or with 0.4 M trehalose by a battery of assays as shown in Table 1. Interestingly, none of the porated conditions was significantly different from any other porated condition regardless of porating agent (i.e. WT vs. H5) and independent of the addition of trehalose ($p < .0300$ for all comparisons). Therefore, it appears that we can load 0.4 M trehalose into fibroblasts with minimal loss to the cell population. In addition, for all conditions tested, cells which were able to attach and spread at 3h were also able to form colonies after one week of culture.

In developing the freezing protocol, the effect of trehalose concentration on the survival of either unporated cells or cells porated with H5 or WT was measured. As reported in Table 2, cells exposed to trehalose did not demonstrate a significant loss of viability of function for concentrations less than 0.4 M independent of poration ($p > 0.5000$ for all comparisons). At 0.6 M, H5 porated cells demonstrated 80% survival, thereby outperforming the WT and unporated conditions by over 20% ($p = .0010$ and $.0065$, respectively). Finally, from 0.8 to 1M, H5 and WT treated populations suffer loss of half of their populations, while unporated cells retained only 10% viability. From this study, it appears that fibroblasts should preferably be exposed to less than or equal to about 0.4 M trehalose in order to maintain high viability.

TABLE 2

Survival of Pre-Freeze Cells: Dose Response of Trehalose

Trehalose (M)	No Poration	WT	H5
0.0	100	90.0±3.6	91.5±2.2
0.2	99.2±3.3	95.6±7.0	98.1±6.4
0.4	98.5±2.6	87.4±0.9	84.1±3.3
0.6	60.7±3.3	52.3±3.2	79.1±3.0
0.8	39.4±1.0	59.5±4.4	52.0±0.9
1.0	9.1±1.6	44.5±2.3	60.6±2.6

EFFECT OF PERMEABILIZATION AND INTRACELLULAR TREHALOSE ON PLUNGE-FROZEN CELLS

The use of trehalose as an intracellular cryoprotectant was demonstrated by testing the survival and function of cells treated with 25 μ g/ml of H5 and 0.4 M trehalose, subsequently plunged in LN₂, and finally thawed in a 37°C water bath. The results demonstrate the effectiveness of trehalose as an intracellular CPA and illustrate the importance of the H5 switch. They are qualitatively outlined in the micrographs of FIG. 2. The first two panels (A, B) show unfrozen and untreated control samples at 3 and 18 hours after plating. Large numbers of cells attach, spread, assume the spindle shape of fibroblasts, and subsequently divide. This is in sharp contrast to the frozen and untreated case (C, D) in which all cells die as a result of the freeze-thaw process. Interestingly, though a moderate fraction of cells treated with WT and loaded with trehalose appear to survive the freeze-thaw protocol (E), these cells are neither able to sustain their viability nor divide properly, resulting in very small populations at 18 hours (F). On the other hand, H5 porated cells loaded with trehalose demonstrate a substantial amount of survival and high plating efficiency (G), as well as a normal degree of cell division resulting in large populations at 18 hours (H).

These data, as well as cell viability at 1 hour, 3 hours and 18 hours, were quantified as shown in FIG. 3. Again, these data demonstrate the consistently high viability and function of cells treated with intracellular trehalose loaded through H5 pores, as compared to all control conditions. For the H5 and trehalose samples, at 1 hour post-thaw, live/dead staining measured $79.0 \pm 6.4\%$ viable cells. At three hours, $66.1 \pm 6.4\%$ cells plated and spread with 211.6 ± 5.2 colonies formed from approximately 200 ± 12 of these functional cells. At 18 hours, the cells formed populations which were $70.8 \pm 2.1\%$ of the size of control populations which were likewise treated with H5 and trehalose but which were not frozen (Table 1). Moreover, these data show no significant difference among time points, implying that cells which were alive at 1h continued to be viable and functioning ($p > .1000$ for all comparisons). In addition, these data are 70-80% higher than all control data to which trehalose was not added ($p < 0.0001$). Further, though at 1 hour the H5 and WT ($81.3 \pm 1.2\%$) conditions treated with trehalose are not statistically different ($p = .8073$), the loss of over 60% of the WT condition's population at 3h ($19.3 \pm 7.3\%$) and 18 hours ($16.9 \pm 3.6\%$), resulted in a large and statistically significant difference between the use of WT and H5 as the porating agent ($p < .0001$). In fact, WT porated cells loaded with trehalose performed so poorly, that their survival was not statistically different from the case in which trehalose was simply acting extracellularly ($p > .4000$). Though non-frozen samples previously indicated little difference between WT and H5 treatment, these post-thaw data indicate a dramatic difference, implying that the engineered H5 is the preferred porating agent for loading trehalose into cells prior the freezing.

EFFECT OF TREHALOSE CONCENTRATION OF PLUNGE-FROZEN CELLS

Since the use of any intracellular CPA requires a balancing between the added freezing protection afforded by higher concentrations and losses due to excessive osmotic forces and toxicity, the effect of trehalose concentration on H5 porated cell survival and growth at 18 hours was measured. These data, as illustrated in FIG. 3, indicated an inverted U-shaped curve, with 0.2 M treated cells performing remarkably well with an 18 hour population of $79.2 \pm 4.0\%$. At 0.1 M the population was significantly lower at $28.6 \pm 3.4\%$ ($p < .0001$) while at higher concentrations the population size steadily decreased, remaining statistically significant from the 0.2 M condition ($p < .0010$). As the concentration increases, the curve flattens which leads to statistically insignificant ($p = .9477$) differences between 0.6 M ($28.5 \pm 2.3\%$) and 0.8 M ($29.4 \pm 2.1\%$). Overall, these data imply that for a freezing protocol with a one step trehalose loading process, 0.2 M is the preferred concentration, providing over 80% survival and function with 3T3 fibroblasts.

EFFICACY OF INTRACELLULAR SUGARS FOR VACUUM DRYING OF CELLS

Fibroblasts were also porated with H5 and loaded with 0.3 M trehalose or sucrose in order to test the efficacy of the preservation method for dried as well as frozen cells. One group of cells was porated with H5 but loaded with PBS only with no sugar for use as a control. Adjusting for cell loss due to handling, poration, etc. using the controls, survival rates of 4% for cells dried in trehalose and 3% for cells dried in sucrose were obtained using a simple ambient temperature vacuum drying step. Periodic microscopic examination of the attached cells over 24 hours indicated that the attached cells were able to maintain the characteristic speed morphology and undergo proliferation. Both trehalose and sucrose were thus shown to be effective in protecting cells subjected to vacuum drying.

CONCLUSIONS

The freezing experiments demonstrate that cells permeabilized with H5 and loaded with less than or equal to about 0.4 M trehalose have a dramatically higher level of viability and function as compared to all other tested conditions. In fact, all controls without trehalose resulted in 100% mortality, while the H5 and trehalose combination resulted in over 70% survival and growth. The presence of trehalose as well as the reversible permeabilization afforded by H5 has multiple advantageous effects which may bolster cell survival. Primarily, intracellular trehalose, by increasing cytosolic viscosity, may inhibit the growth of intracellular ice crystals, thus mitigating cell damage. Further, as has been demonstrated for isolated biomaterials, trehalose may stabilize cell membranes and proteins during freezing, thereby preventing membrane leakiness and favoring native protein configuration. Likewise, sample stability may be improved by trehalose's ability to permit a higher temperature glass transition in the unfrozen fraction.

Though both the H5 and WT conditions have presumably similar intracellular trehalose contents, the H5 condition demonstrated 56% higher survival and growth. This result underscores the advantage of the zinc-actuated switch. Since DMEM with serum (post-thaw medium) contains μM concentrations of Zn^{2+} ions, the H5 pores are blocked under these post-thaw conditions. Thus, the cells treated with the engineered and switchable H5 molecules and subsequently plated in DMEM with serum regain their natural permeability to small molecules, permitting a return to normal homeostasis and subsequent recovery. Without the benefit of the resealing, WT permeabilized cells cannot recover properly post-thaw, and they ultimately die. As suggested above, under certain limited circumstances it may be possible to reversibly permeabilize target cells with WT where the WT pores are unstable and are shed by the cells before the cells die off from the permeabilization effects.

Although the initial freezing experiments used 0.4 M trehalose, the maximum concentration indicated by pre-freeze evaluation, the effect of varying the trehalose concentration on the post-thaw survival of H5-permeabilized cells was evaluated by varying the trehalose dose up to 1.0 M. The resulting trehalose dose response is represented by an inverted U-shaped curve with a maximal survival of over 80%, at 0.2 M. Apparently, below 0.2 M there is not adequate trehalose present to afford proper protection. Above this, the loss of viability seems to be a direct result of exposing the cells to excessive osmotic pressure during loading and of not removing the trehalose after thawing.

To probe the mechanism of trehalose protection and test whether intracellular ice formation occurs under the exemplary conditions, the temperature excursion of plunge-frozen H5 and trehalose treated samples was measured with a thermocouple, and the measured cooling rates reproduced on a cryomicroscope. Fairly independent of position, plunged cells experienced a cooling rate of $-70^{\circ}\text{C}/\text{min}$ from 22°C to -15°C , and $-160^{\circ}\text{C}/\text{min}$ to -175°C with a latent heat release at -12 to -15°C . When fibroblasts treated with H5 and loaded with trehalose were deliberately exposed to this cooling protocol on a cryomicroscope, cells darkened following the seeding of extracellular ice, including that intracellular ice had formed. If this indeed reflects what occurs in the cryovial, the trehalose must somehow protect the cell from the damaging effects of intracellular ice formation.

Often, preservation protocols have been evaluated at times shortly following thaw, resulting in the presumption of success. The data presented here demonstrates that such testing is not a reliable indicator of a protocol's effectiveness. For the plunge freeze experiments, the earliest fluorescent tests for cell viability are not indicative of the final condition of cell populations.

At 15 minutes, all frozen conditions, except untreated controls, demonstrate 60-80% viability. However, after one hour cells treated only with either H5 or WT retain 10% viability, and cells with trehalose added alone have 45% viability. Only cells treated with both a porating agent and trehalose retain 70-80% viability and function after 1 hour. Further, as indicated by plating at 3 hours and growth at 18 hours, the H5 and trehalose condition leads to long term cell survival and function. These data imply that damage due to freezing stresses, at least in part, does not result in the immediate destruction of cells, but rather in a gradual loss of viability.

The Examples show the successful cryopreservation of 3T3 murine fibroblasts using less than or equal to 0.4 M trehalose as the sole CPA in a rather simple LN₂ plunge cryopreservation protocol. The trehalose concentration used is an order of magnitude lower than what is required for mammalian cells in traditional constructs utilizing traditional CPAs. Survival, however, is dependent on the reversible permeabilization afforded by the H5 switchable pore. Further, freezing and thawing took place in a rather large sample volume (~1 ml) and without any regard for the cooling profile, seeding temperature, or plunge temperature. This suggests that the use of small carbohydrates introduced intracellularly can allow the preservation of living material using low concentrations of CPA, thus avoiding toxicity effects, and implementing simplified freezing protocols.

The efficacy of intracellular trehalose was also shown for vacuum dried fibroblasts. Vacuum drying at ambient temperature of reversibly porated fibroblasts loaded with trehalose or sucrose resulted in viable cells after rehydration.

It will be understood that the foregoing is only illustrative of the principles of the invention, and that various modifications can be made by those skilled in the art without departing from the scope and spirit of the invention. All references cited herein are expressly incorporated by reference in their entirety.

What is claimed is:

- 1
2 *sub*
3 *B1*
4
5
6
7
8
9
10
- ①. A method for preserving biological material having lipid membranes, comprising:
- a. Reversibly porating the lipid membranes of the biological material;
 - b. Loading the biological material with an agent having bio-preservation properties to a predetermined intracellular concentration;
 - c. Preparing the bio-preservation agent loaded biological material for storage;
 - d. Storing the prepared biological material;
 - e. Recovering the stored biological material from storage; and
 - f. Reversing the cell membrane poration.

2. The method of claim 1, wherein the biological material comprises nucleated mammalian cells.

3. The method of claim 2, wherein the biological material is selected from the group consisting of hepatocytes, fibroblasts, chondrocytes, keratinocytes, islets of Langerhans and hematopoietic cells.

4. The method of claim 1, wherein the bio-preservation agent comprises a substantially non-permeating sugar having bio-preservation properties.

1
2
3

5. The method of claim 4, wherein the sugar having bio-preservation properties is selected from a group consisting of trehalose, sucrose, glucose, and maltose.

1
2
3

6. The method of claim 1, wherein the biological material is loaded with an intracellular concentration of bio-protective agent less than or equal to about 1.0 M.

1 7. The method of claim 6, wherein the biological material is loaded with
2 an intracellular concentration of bio-protective agent less than or equal to
3 about 0.4 M.

1 8. The method of claim 1, wherein the lipid membranes are reversibly
2 porated using a *Staphylococcus aureus* α -toxin.

1 9. The method of claim 1, wherein the lipid membranes are reversibly
2 porated using H5 α -toxin.

10. The method of claim 1, wherein the biological material is prepared for
storage by freezing to cryogenic temperatures.

11. The method of claim 1, wherein the biological material is prepared for
storage by freeze drying.

12. The method of claim 1, wherein the biological material is prepared for
storage by vacuum or air drying.

13. A method for dry storing living nucleated cells, comprising:

- a. Reversibly porating the cell membranes of the nucleated cells;
- b. Loading a sugar having bio-preservation properties to a predetermined intracellular concentration;
- c. Drying the sugar loaded cells;
- d. Placing the dried cells in dry storage;
- e. Rehydrating the dried cells; and
- f. Reversing the cell membrane poration.

1 14. The method of claim 11, wherein the cell membranes are reversably
2 porated using H5 α -toxin.

1 15. The method of claim 14, wherein the sugar having bio-preservation
2 properties is selected from a group consisting of trehalose, sucrose, glucose
3 and maltose.

1 16. The method of claim 15, wherein the biological material is loaded with
2 an intracellular concentration of sugar less than or equal to about 1.0 M.

1 17. The method of claim 16, wherein the biological material is loaded with
2 an intracellular concentration of sugar less than or equal to about 0.4 M.

1 18. The method of claim 16, wherein sugar is the only bio-protective agent
2 employed.

1 19. The method of claim 16, wherein the drying is accomplished by freeze
2 drying.

1 20. The method of claim 19, wherein the sugar loaded cells are plunge
2 frozen to a cryogenic temperature.

1 21. The method of claim 16, wherein the drying is a vacuum or air drying.

1 22. The method of claim 21, wherein the drying is performed at about
2 ambient temperature.

1 23. A method for cryopreserving nucleated cells having cell membranes,
2 comprising:

- 3 a. Reversibly porating the cell membranes of the nucleated cells;
4 b. Loading the porated cells with a bio-preservation agent to a
5 predetermined intracellular concentration;
6 c. Freezing the sugar loaded cells to a cryogenic temperature;
7 d. Storing the frozen biological material at a cryogenic temperature;
8 e. Thawing the cryo-stored biological material; and
9 f. Reversing the cell membrane poration.

24. The method of claim 23, wherein the cell membranes are reversibly
porated using a *Staphylococcus aureus* α -toxin.

25. The method of claim 23, wherein the cell membranes are reversibly
porated using H5 α -toxin.

26. The method of claim 23, wherein the bio-preservation agent comprises
a substantially non-permeating sugar having bio-preservation properties.

27. The method of claim 26, wherein the sugar having bio-preservation
properties is selected from a group consisting of trehalose, sucrose, glucose,
and maltose.

28. The method of claim 26, wherein the biological material is loaded with
an intracellular concentration of sugar less than or equal to about 1.0 M.

29. The method of claim 28, wherein the biological material is loaded with
an intracellular concentration of sugar less than or equal to about 0.4 M.

1 30. The method of claim 26, wherein the sugar loaded cells are plunge
2 frozen to a cryogenic temperature.

1 31. The method of claim 23, wherein the bio-preservation agent is a
2 conventional penetrating cryoprotective agent.

1 32. The method of claim 31, wherein the bio-preservation agent is selected
2 from the group consisting of DMSO, glycerol and ethylene glycol.

1 33. A method for cryopreserving living nucleated mammalian cells having
2 cell membranes, comprising:

a. Reversably porating the cell membranes of the nucleated cells using
H5 α -toxin;

b. Loading the porated cells with a bio-preservation agent consisting of
a sugar to a predetermined intracellular concentration that is less than or equal
to about 1.0 M;

c. Freezing the sugar loaded cells to a cryopreservation temperature;

d. Storing the frozen biological material at a cryo-storage temperature;

e. Thawing the cryo-stored biological material; and

f. Reversing the cell membrane poration.

1 34. The method of claim 33, wherein the sugar having bio-preservation
2 properties is selected from a group consisting of trehalose, sucrose, glucose
3 and maltose.

1 35. The method of claim 34, wherein the intracellular concentration of the
2 sugar is less than or equal to about 0.4 M.

1 36. The method of claim 34, wherein the cells are plunge frozen.




FIG. 1







FIG. 2



Survival Rate Following Freeze-Thaw Protocol
FIG. 3



Extracellular Trehalose (M)
Survival Following Freeze-Thaw Protocol
for Varying Concentrations of Trehalose



Post Hydration Results After Vacuum Drying

FIG. 5

Declaration, Petition and Power of Attorney For Patent Application

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name,

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

CONTROLLED REVERSIBLE PORATION FOR
PRESERVATION OF BIOLOGICAL MATERIALS

the specification of which

(check one)

___ is attached hereto.

X was filed on September 11, 1998 . as

Application Serial No. 09/151,821

and was amended on _

(if applicable)

I do not know and do not believe that the subject matter of this application was ever known or used in the United States before my invention thereof or patented or described in any printed publication in any country before my invention thereof or more than one year prior to the date of this application, and that said subject matter has not been patented or made the subject of an issued inventor's certificate in any country foreign to the United States on an application filed by me or my legal representatives or assigns more than twelve months prior to the date of this application; that I acknowledge my duty to disclose information of which I am aware which is material to the examination of this application, that no application for patent or inventor's certificate on the subject matter of this application has been filed by me or my representatives or assigns in any country foreign to the United States, except those identified below, and that I have reviewed and understand the contents of the specification, including the claims as amended by any amendment referred to herein.

I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

PRIORITY CLAIM

I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

Check one:

☒ no such applications have been filed.

☐ such applications have been filed as follows

EARLIEST FOREIGN APPLICATION(S), IF ANY FILED WITHIN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

Country	Application Number	Date of Filing (month,day,year)	Priority Claimed Under 35 USC 119
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No
			<input type="checkbox"/> Yes <input type="checkbox"/> No

ALL FOREIGN APPLICATION(S), IF ANY FILED MORE THAN 12 MONTHS
(6 MONTHS FOR DESIGN) PRIOR TO THIS U.S. APPLICATION

CLAIM FOR BENEFIT OF EARLIER U.S./PCT APPLICATION(S)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose to the Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application. As to subject matter of this application which is common to my earlier United States application, if any, described below, I do not believe that the same was ever known or used in the United States before my invention thereof or patented or described in any printed publication in any country before my invention thereof or more than one year prior to said earlier application, or in public use or on sale in the United States more than one year prior to said earlier application, that the said common subject matter has not been patented or made the subject of an inventor's certificate issued before the date of said earlier application in any country foreign to the United States on an application, filed by me or my legal representatives or assigns more than twelve months prior to said application and that no application for patent or inventor's certificate on said subject matter has been filed by me or my representatives or assigns in any country foreign to the United States except those identified herein.

(Application Serial No.)	(Filing Date)	(Status) (patented,pending,aband.)
--------------------------	---------------	---------------------------------------

(Application Serial No.)	(Filing Date)	(Status) (patented,pending,aband.)
--------------------------	---------------	---------------------------------------

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorneys and/or agents to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

William C. Geary III	Reg. No. 31,359
John Christopher	Reg. No. 37,596
Christopher S. Daly	Reg. No. 37,303
Judith C. Crowley	Reg. No. 35,091
Ronald E. Cahill	Reg. No. 38,403
Paul D. Durkee	Reg. No. 41,003
Cedric G. DeLaCruz	Reg. No. 36,498
Carl M. DeFranco	Reg. No. 32,675
Michael I. Falkoff	Reg. No. 30,833

Send Correspondence to: Ronald E. Cahill

Nutter, McClennen & Fish, LLP, One International Place, Boston, MA 02110-2699

Direct Telephone Calls to: Attorney: Ronald E. Cahill Telephone No. (617) 439-2782

Wherefore I petition that letters patent be granted to me for the invention or discovery described and claimed in the attached specification and claims, and hereby subscribe my name to said specification and claims and to the foregoing declaration, power of attorney, and this petition.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Mehmet Toner	
Inventor's signature <i>Mehmet Toner</i>	Date Nov 11, 98
Residence 100 Pilgrim Road, Wellesley, Massachusetts 02481	
Citizenship Turkey	
Post Office Address (if different)	

Full name of second/joint inventor, if any Michael Russo	
Inventor's signature <i>Michael J. Russo</i>	Date 12/2/98
Residence 22 Pleasant Street, Wakefield, Massachusetts 01880	
Citizenship United States	
Post Office Address (if different)	

Full name of third/joint inventor, if any Robert Bieganski	
Inventor's signature <i>ROBERT BIEGANSKI</i>	Date DEC 8, 98
Residence	
Citizenship United States	
Post Office Address (if different) P.O. Box 425845, Cambridge, Massachusetts 02142-0016	

529489_1.WP6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**APPLICANT:** Mehmet Toner, Michael Russo and Robert Bieganski**ATTORNEY DOCKET NO.:** 22727-17**APPLICATION NO.:** 09/151,821**EXAMINER:** N/A**FILED:** September 11, 1998**GROUP NO.:** 1643**ENTITLED:** CONTROLLED REVERSIBLE PORATION FOR PRESERVATION OF BIOLOGICAL MATERIALS

VERIFIED STATEMENT AS SMALL ENTITYAssistant Commissioner for Patents
Washington, D.C. 20231**Sir:****WE UNDERSIGNED DECLARE(S):**

Exclusive rights in the above-identified invention reside in the "small entity(ies)" defined and named below, and Massachusetts Institute of Technology, and "small entity" fees are appropriate. Qualification as a small entity is based upon the appropriately checked statements below:

INDEPENDENT INVENTOR(S)

The below-signing independent inventor(s) has (have) not assigned, granted, conveyed or licensed, and is (are) under no obligation under contract or law to assign, grant, convey or license any rights in the invention to any person who could not likewise be classified as an independent inventor under 37 C.F.R. § 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 C.F.R. § 1.9(d) or a nonprofit organization under 37 C.F.R. § 1.9(e).

SMALL BUSINESS CONCERN

The below-identified small business concern qualifies as a small business as defined in 13 C.F.R. § 121.3-18, and reproduced in 37 C.F.R. § 1.9(d), for purposes of paying reduced fees under Sections 41(a) and (b) of Title 35, in that the number of employees, including those of its affiliates, which does not exceed 500 persons, and it has not assigned, granted, conveyed or licensed, and is under no obligation under contract or law to assign, grant, convey or license, any rights in the invention to any person who could not be classified as an independent inventor if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 C.F.R. § 1.9(d) or a nonprofit organization under 37 C.F.R. § 1.9(e).

Concerns are affiliates of each other when, either directly or indirectly, one concern controls or has the power to control the other, or a third party controls or has the power to control both. The number of employees of the business concern is the average over the fiscal year of the persons employed during each of the pay periods of the fiscal year. Employees are those persons employed on a full-time, part-time or temporary basis during the previous fiscal year of the concern.

☒ **NONPROFIT ORGANIZATION** (Check additional applicable box)

The below-identified nonprofit organization qualifies as a small entity under 37 C.F.R. § 1.9(e) in that it constitutes:

1. ☐ a university or other institution of higher education located in any country; or
2. ☒ an organization of the type described in Section 501(c)(3) of the Internal Revenue Code of 1954 (26 U.S.C. § 501(c)(3)) and exempt from taxation under Section 501(a) of the Internal Revenue Code (26 U.S.C. § 501(a)); or
3. ☐ any nonprofit scientific or educational organization qualified under a nonprofit organization statute of a state of the United States (35 U.S.C. § 201(i)); or
4. ☐ any nonprofit organization located in a foreign country which would qualify as a nonprofit organization under paragraphs (e)(2) or (3) of Rule 1.9 if it were located in the United States.

I, undersigned, acknowledge(s) the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of filing, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate (37 C.F.R. § 11.28(b)).

I, below-signing individual(s) hereby declare(s) that (he, she, they) are authorized to execute this application on behalf of the small entity; that all statements made herein of (his, her, their) own knowledge are true and that all statements made on information and belief are believed to be true; further that these statements were made with the knowledge that willful false statements and the same so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issue thereon, or any patent to which this verified statement is directed.

Name of Small Entity: (Independent Inventor/Small Business/Nonprofit)
The General Hospital Corporation

Address of Small Entity: (Street, City, State or Country, Zip Code)
55 Fruit Street, Boston, MA 02114

Name of Person Signing: (Small Business/Nonprofit)


~~Jain D. Miller, Ph.D.~~ **DAVID J. GLASS, PH.D.**

DJG

Title of Person Signing: (Small Business/Nonprofit) **ASSOCIATE DIRECTOR FOR PATENTS,**
~~Intellectual Property and Agreement Specialist, Office of Technology Affairs~~

DJG

Signature: (Please sign and date in permanent ink.)

X 

Date signed:

X *Oct. 21, 1998*

Applicant or Patentee: Mehmet Toner et al.

Serial or Patent No.: 09/151,821

Attorney's Docket No.:22727-17

MIT Case No.: MIT 7459

Filed or Issued: September 11, 1998

For: Controlled Reversible Poration for Preservation of Biological Materials

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) and 1.27(d)) - NONPROFIT ORGANIZATION**

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF ORGANIZATION: Massachusetts Institute of Technology
ADDRESS OF ORGANIZATION: 77 Massachusetts Avenue
Cambridge, MA 02139

TYPE OF ORGANIZATION

- ☒ UNIVERSITY OR OTHER INSTITUTION OF HIGHER EDUCATION
- ☐ TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE
(26 USC 501(a) and 501(c) (3))
- ☐ NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF
STATE OF THE UNITED STATES OF AMERICA
(NAME OF STATE _____)
(CITATION OF STATUTE _____)
- ☐ WOULD QUALIFY AS TAX EXEMPT UNDER INTERNAL REVENUE
SERVICE CODE (26 USC 501(a) and 501(c) (3)) IF LOCATED IN THE
UNITED STATE OF AMERICA
- ☐ WOULD QUALIFY AS NONPROFIT SCIENTIFIC OR EDUCATIONAL
UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA
IF LOCATED IN THE UNITED STATES OF AMERICA
(NAME OF STATE _____)
(CITATION OF STATUTE _____)

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 CFR 1.9(e) for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code with regard to the invention entitled Controlled Reversible Poration for Preservation of Biological Materials by inventor(s) Mehmet Toner et al. described in

- ☐ the specification filed herewith.
- ☒ application serial no. 09/151,821 , filed September 11, 1998.
- ☐ patent no. , issued .

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to the above identified invention.

If the rights held by the nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who could not qualify as an independent inventor under 37 CFR 1.9 (c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under CFR 1.9(e). *NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

NAME _____
ADDRESS _____
()INDIVIDUAL ()SMALL BUSINESS CONCERN ()NONPROFIT ORGANIZATION

NAME _____
ADDRESS _____
()INDIVIDUAL ()SMALL BUSINESS CONCERN ()NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING

Jarmila Z. Hrbek

TITLE IN ORGANIZATION

Patent Administrator and Office Manager,
Technology Licensing Office

ADDRESS OF PERSON SIGNING

77 Massachusetts Avenue, Room NE25-230
Cambridge, MA 02139

SIGNATURE

Jarmila Z. Hrbek

DATE

October 15, 1998